Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Stock Information for Equillium Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Equillium Inc.

Equillium to Participate in Upcoming Investor Conferences
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
Equillium to Participate in Upcoming Investor Conferences
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
Equillium Announces Leadership and Corporate Updates
NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.